A5043618026- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
- Renal and related cancers
- Esophageal Cancer Research and Treatment
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Cancer, Hypoxia, and Metabolism
- Cancer Treatment and Pharmacology
- Prostate Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cancer Research and Treatments
- Ureteral procedures and complications
- Cancer Cells and Metastasis
- Advances in Oncology and Radiotherapy
- Cancer, Lipids, and Metabolism
- Nutrition, Genetics, and Disease
- BRCA gene mutations in cancer
Fox Chase Cancer Center
2017-2025
Temple University Health System
2018-2022
No AccessJournal of UrologyAdult Urology1 Jul 2022The Role Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis Pooja Ghatalia, Elizabeth A. Handorf, Daniel M. Geynisman, Mengying Deng, Matthew R. Zibelman, Philip Abbosh, Fern Anari, Richard E. Greenberg, Rosalia Viterbo, David Chen, Marc C. Smaldone, Alexander Kutikov, and Robert G. Uzzo GhataliaPooja Ghatalia †Correspondence: Department Hematology/Oncology, Fox Chase Cancer Center, 333...
438 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy or chemoradiation is the standard of care for urothelial carcinoma (UC) patients with MIBC. Both and have short long-term toxicity QOL implications. Mutations in DNA damage repair/response genes are associated pathologic downstaging after NAC. We hypothesized that a combination biomarker selection clinical staging would identify prospectively avoidance algorithm. Methods: conducted single-arm, phase II,...
397 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy (Cx) or chemoradiation (CRT) is the standard of care for urothelial carcinoma (UC) pts with muscle invasive bladder cancer (MIBC). Both Cx and CRT have potential short long-term toxicity QOL implications. Mutations in DNA damage repair/response genes are associated pathologic downstaging after NAC. Methods: We conducted a phase II, multi-institutional clinical trial (NCT02710734) to evaluate risk-adapted...
Immune checkpoint blockade (ICB) is an approved therapy for advanced metastatic mismatch repair (MMR)-deficient cancer regardless of tissue origin. Although effective initially, recurrence rates are significant, and long-term outcomes remain poor most patients. It not currently recommended to give sequential ICB MMR-deficient colorectal (CRC) or patients with from Lynch syndrome. The need subsequent options in beyond the first regimen arises clinical practice, there often no standard...
Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with new combination therapies demonstrating improved response rates and survival. There are no head-to-head prospective trials comparing an immunotherapy doublet immunotherapy/tyrosine-kinase inhibitor-based combination. We compare real-world outcomes in patients treated axitinib/pembrolizumab (axi/pembro) or ipilimumab/nivolumab (ipi/nivo). The primary endpoints were overall-survival (OS) progression-free survival...
815 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) or chemoradiation (CRT) is the standard of care for patients (pts) with muscle invasive bladder cancer (MIBC). Mutations in DNA damage repair genes enrich pathologic downstaging after NAC. In RETAIN-1, a risk-adapted approach was employed to identify cystectomy-sparing active surveillance (AS) following NAC, reporting 73% 2-year MFS rate. RETAIN-2 employs similar but incorporates...
548 Background: Combination tyrosine kinase inhibitors (TKIs) and immune checkpoint (IO) are an established standard of care for patients with metastatic renal cell carcinoma (mRCC). We report updated analysis a multi-center, investigator-initiated (IIT), phase I/II study axitinib (axi) nivolumab (nivo) in the previously treated patient cohort. Methods: The investigated combination axi/nivo initial dose finding I portion II including 2 parallel arms: treatment naïve mRCC TKIs or IO/IO...
Background: Liquid biopsy (LB) captures dynamic genomic alterations (alts) across metastatic colorectal cancer (mCRC) therapy and may complement tissue (TB). We sought to describe the utility of LB better understand mCRC biology during therapy. Methods: Thirty-three patients (pts) with underwent LB. used permutation-based t -tests assess associations between alts, clinical variables Kendall's tau measure correlations. Results: Of 33 pts, 15 were women; 22 had colon, rest rectal cancer. Pts...
PURPOSE Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are associated pathologic downstaging after NAC. We hypothesized that a combination biomarker selection and clinical staging would identify cystectomy-sparing active surveillance (AS). PATIENTS AND METHODS conducted single-arm, phase II, noninferiority trial to evaluate risk-adapted approach MIBC....
378 Background: The WHO recognizes multiple variant histologies of urothelial carcinoma (vUC), many which have been associated with poor outcomes compared (UC). We aimed to explore molecular differences between aggressive vUC and UC. Methods: 23 micropapillary (MP), 16 plasmacytoid (P), sarcomatoid (S), 7 nested (N), 6 clear cell (CC), 2 giant (GC) specimens were tested 2012 2018 via a multiplatform profiling service (Caris Life Sciences, Phoenix, AZ) consisting gene sequencing (next...
4536 Background: Although cisplatin-based neoadjuvant chemotherapy (NAC) has demonstrated an overall survival (OS) benefit in MIBC, only a subset of patients have pathologic complete response (pT0) at cystectomy. ATM, RB1 and FANCC mutations shown correlation with pT0 to NAC, as previously published. We now report updated OS disease specific (DSS) from two phase II trials using these gene alterations biomarkers. Methods: Patients stage T2-T4 (N0 or N1) MIBC were enrolled dose-dense NAC MVAC...
4582 Background: The role of CN in mRCC was challenged by the results CARMENA trial targeted therapy (TT) era. We sought to evaluate both upfront and deferred pts receiving modern IO-based TT regimens. Methods: Pts with synchronous who received systemic (tx) for after 2011 were included from de-identified nationwide Flatiron Health database. evaluated 3 groups: tx alone, systemic-> CN, CN-> tx. Overall survival (OS) calculated time initiation first – or CN. Patient characteristics...
4551 Background: Front-line treatment for patients (pts) with metastatic clear cell renal carcinoma (mRCC) has undergone rapid advances in the last five years. This evolution led to uncertainty about optimal first line combination regimen. Herein, we compare real-world outcomes pts treated either axitinib/pembrolizumab (A/P) or ipilimumab/nivolumab (I/N) reported by International Metastatic RCC Database Consortium (IMDC) score. Methods: The nationwide Flatiron Health electronic health...
399 Background: Adenocarcinoma (ADA) and squamous cell carcinoma (SCC) are rare, aggressive subtypes of bladder cancer, for which no clear standard care exists. We report on survival pts with ADA SCC identify potential therapeutic targets using molecular profiling via next generation sequencing (NGS). Methods: Survival trends, demographics, pt characteristics were obtained from the Surveillance, Epidemiology, End Results (SEER) Database. In a separate cohort, NGS results 72 specimens (50%...
75 Background: Medical oncology fellowship training presents a critical time for developing skills necessary discussing end of life (EOL) care preferences with patients and delivering EOL care. There is little data exploring the delivery by fellows in practice. We describe our fellows’ experience identify areas to improve communication. Methods: retrospectively reviewed electronic medical records (EMR) at center advanced (metastatic or recurrent) solid tumors who received clinics died...
523 Background: Neoadjuvant cisplatin-based chemotherapy (NAC) followed by cystectomy is the standard of care for muscle-invasive urothelial bladder cancer (MIBC). 15-35% MIBC patients present with ureteral obstruction. Poor renal function increases cisplatin toxicity. It unknown whether obstruction which has been relieved (whether nephrostomy tube or nephroureteral stent) have same risk toxicity as without Methods: We retrospectively reviewed an institutional database all undergoing NAC...
291 Background: Combination systemic therapy with tyrosine kinase inhibitors (TKIs) and an immune checkpoint inhibitor (IO) are established standard of care for patients metastatic renal cell carcinoma (mRCC). We performed a phase I/II study to investigate the safety efficacy combining TKI axitinib (axi) IO agent nivolumab (nivo). Methods: This investigated combination axi nivo in initial dose finding I portion 3+3 design determine recommended 2 (RP2D) axi. The II included parallel arms:...
To determine whether patients with carcinoma invading bladder muscle (MIBC) and ureteric obstruction can safely receive cisplatin-based neoadjuvant chemotherapy (C-NAC), to such require relief of a stent or percutaneous nephrostomy prior beginning C-NAC.We performed single-institution retrospective analysis MIBC receiving C-NAC falling into three groups: no (NO); relieved (RO); unrelieved (URO). address C-NAC, we compared NO those RO, the primary outcome premature discontinuation....